

May 30, 2018

Supernus to Present at the 2018 Jefferies Healthcare Conference

ROCKVILLE, Md., May 30, 2018 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that the Company's management will present an overview and update of the Company's business, and host investor meetings at the Jefferies 2018 Global Healthcare Conference.

Date: Tuesday, June 5, 2018

Time: 11:00 a.m. ET

Place: Grand Hyatt New York in New York City

Investors interested in arranging a meeting with the Company's management during this conference should contact the conference coordinator.

A live webcast of the presentation can be accessed by visiting 'Events & Presentations' in the Investor Relations section on the Company's website at www.supernus.com. An archived replay of these webcasts will be available for 60 days after the conference on the Company's website.

About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company currently markets Trokendi XR® (extended-release topiramate) for the prophylaxis of migraine headache and the treatment of epilepsy, and Oxtellar XR® (extended-release oxcarbazepine) for the treatment of epilepsy. The Company is also developing several product candidates to address large market opportunities in psychiatry, including SPN-810 for the treatment of Impulsive Aggression in ADHD patients and SPN-812 for the treatment of ADHD.

CONTACT:

Jack A. Khattar, President and CEO Gregory S. Patrick, Vice President and CFO Supernus Pharmaceuticals, Inc.

Tel: (301) 838-2591

Or

Investor Contact: Peter Vozzo Westwicke Partners Office: (443) 213-0505 Mobile: (443) 377-4767

Email: peter.vozzo@westwicke.com



Source: Supernus Pharmaceuticals, Inc.

News Provided by Acquire Media